The spectrum of haemostatic abnormalities in glucocorticoid excess and defect

European Journal of Endocrinology

Volumn 173, Issue 3, 2015, Pages R101-R113

  Isidori, Andrea M ^a   Minnetti, Marianna ^a,b   Sbardella, Emilia ^a   Graziadio, Chiara ^a   Grossman, Ashley B ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; GLUCOCORTICOID; HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; THROMBIN ANTITHROMBIN COMPLEX; THROMBOXANE B2; VON WILLEBRAND FACTOR; WARFARIN;

ADDISON DISEASE; BLEEDING RISK; BLOOD CLOTTING DISORDER; CUSHING SYNDROME; ENZYME BLOOD LEVEL; FIBRINOLYSIS; HUMAN; HYPERCORTISOLISM; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; REVIEW; RISK; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; BLOOD COAGULATION DISORDERS; CHEMICALLY INDUCED; COMPLICATION; METABOLISM; THROMBOCYTOSIS;

BLOOD COAGULATION DISORDERS; CUSHING SYNDROME; FACTOR VIII; FIBRINOGEN; GLUCOCORTICOIDS; HUMANS; THROMBOCYTOSIS; THROMBOXANE B2; VENOUS THROMBOEMBOLISM; VON WILLEBRAND FACTOR;

EID: 84940641527     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0308     Document Type: Review

References (115)

1. Spronk HM, Govers-Riemslag JW & ten Cate H. The blood coagulation system as a molecular machine. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology 2003 25 1220-1228. (doi:10.1002/bies.10360)
2. Orwoll ES & Orwoll RL. Hematologic abnormalities in patients with endocrine and metabolic disorders. Hematology/Oncology Clinics of North America 1987 1 261-279.
3. Targher G, Pichiri I, Zoppini G, Bonora E & Chonchol M. Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review. Seminars in Thrombosis and Hemostasis 2009 35 605-612. (doi:10.1055/s-0029-1242714)
4. Jacoby RC, Owings JT, Ortega T, Gosselin R & Feldman EC. Biochemical basis for the hypercoagulable state seen in Cushing syndrome; discussion 1006-7. Archives of Surgery 2001 136 1003-1006. (doi:10.1001/archsurg.136.9.1003)
5. van der Pas R, Leebeek FW, Hofland LJ, de Herder WW & Feelders RA. Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. Clinical Endocrinology 2013 78 481-488. (doi:10.1111/cen.12094)
6. Graversen D, Vestergaard P, Stochholm K, Gravholt CH & Jorgensen JO. Mortality in Cushing's syndrome: a systematic review and meta-analysis. European Journal of Internal Medicine 2012 23 278-282. (doi:10.1016/j.ejim.2011.10.013)
7. Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, Pereira AM & Sorensen HT. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. Journal of Clinical Endocrinology and Metabolism 2013 98 2277-%2284. (doi:10.1210/jc.2012-3582)
8. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A & Johannsson G. Premature mortality in patients with Addison's disease: a populationbased study. Journal of Clinical Endocrinology and Metabolism 2006 91 4849-4853. (doi:10.1210/jc.2006-0076)
9. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH & Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clinical Endocrinology 1997 46 75-81. (doi:10.1046/j.1365-2265.1997. d01-1749.x)
10. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism.West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357 425-431. (doi:10.1016/S0140-6736(00)04006-X)
11. Pivonello R, De Martino MC, De Leo M, Lombardi G & Colao A. Cushing's syndrome. Endocrinology and Metabolism Clinics of North America 2008 37 135-149, ix. (doi:10.1016/j.ecl.2007.10.010)
12. Miljic P, Miljic D, Cain JW, Korbonits M & Popovic V. Pathogenesis of vascular complications in Cushing's syndrome. Hormones 2012 11 21-30.
13. Trementino L, Arnaldi G, Appolloni G, Daidone V, Scaroni C, Casonato A & Boscaro M. Coagulopathy in Cushing's syndrome. Neuroendocrinology 2010 92 (Suppl 1) 55-59. (doi:10.1159/000314349)
14. Avellone G, Di Garbo V, Cordova R, Rotolo G, Abruzzese G, Raneli G, De Simone R & Bompiani GD. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Research 1994 25 85-92.
15. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R & Bompiani G. Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution. Thrombosis Research 199475 223-231. (doi:10.1016/0049-3848(94)90233-X)
16. Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A & Martino E. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery. European Journal of Endocrinology 2010 163 783-791. (doi:10.1530/EJE-10-0583)
17. Mustard JF, Kinlough-Rathbone RL & Packham MA. Mechanisms in thrombosis. Agents and Actions. Supplements 1984 15 9-23.
18. Sato T, Hiramatsu R, Iwaoka T, Fujii Y, Shimada T & Umeda T. Changes of platelets, serum lactic dehydrogenase, g-glutamyltranspeptidase, choline esterase and creatine phosphokinase levels in patients with Cushing's syndrome. Tohoku Journal of Experimental Medicine 1984 142 195-200. (doi:10.1620/tjem.142.195)
19. Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O & Onder EH. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombinactivatable fibrinolysis inhibitor levels. Journal of Endocrinological Investigation 2009 32 169-174. (doi:10.1007/BF03345709)
20. Lang F, Gawaz M & Borst O. The serum- & glucocorticoid-inducible kinase in the regulation of platelet function. Acta Physiologica 2015 213 181-190. (doi:10.1111/apha.12334)
21. Karamouzis I, Berardelli R, D'Angelo V, Fussotto B, Zichi C, Giordano R, Settanni F, Maccario M, Ghigo E & Arvat E. Enhanced oxidative stress and platelet activation in patients with Cushing's syndrome. Clinical Endocrinology 2015 82 517-524. (doi:10.1111/cen. 12524)
22. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacology & Therapeutics 2008 118 18-35. (doi:10.1016/j.pharmthera.2008.01.001)
23. Stel HV, Sakariassen KS, de Groot PG, van Mourik JA & Sixma JJ. Von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985 65 85-90.
24. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S & Girolami A. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagulation & Fibrinolysis 1999 10 145-151. (doi:10.1097/00001721-199904000-00006)
25. Patrassi GM, Sartori MT, Viero ML, Scarano L, BoscaroM& Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagulation & Fibrinolysis 1992 3 789-793. (doi:10.1097/00001721-199212000-00013)
26. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM & Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 3662-3666. (doi:10.1210/jcem.87.8.8703)
27. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F & Mannucci PM. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. Journal of Endocrinological Investigation 2000 23 145-150. (doi:10.1007/BF03343697)
28. Chopra A, Kumar R, Kishore K, Tandon N, Yusuf T, Kumar S, Mishra P & Saxena R. Effect of glucocorticoids on von Willebrand factor levels and its correlation with von Willebrand factor gene promoter polymorphism. Blood Coagulation & Fibrinolysis 2012 23 514-519. (doi:10.1097/MBC.0b013e3283548dfc)
29. Casonato A, Daidone V, Sartorello F, Albiger N, Romualdi C, Mantero F, Pagnan A & Scaroni C. Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. British Journal of Haematology 2008 140 230-235. (doi:10.1111/j.1365-2141.2007.06907.x)
30. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, Gerdes VE, Bller HR & Brandjes DP. Hypercoagulable state in Cushing's syndrome: a systematic review. Journal of Clinical Endocrinology and Metabolism 2009 94 2743-2750. (doi:10.1210/jc.2009-0290)
31. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M & Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. Journal of Clinical Endocrinology and Metabolism 1999 84 2664-2672. (doi:10.1210/jcem.84.8.5896)
32. Koutroumpi S, Spiezia L, Albiger N, Barbot M, Bon M, Maggiolo S, Gavasso S, Simioni P, Frigo A, Mantero F et al. Thrombin generation in Cushing's syndrome: do the conventional clotting indices tell the whole truth? Pituitary 2014 17 68-75. (doi:10.1007/s11102-013-0467-3)
33. Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Salek SZ, Jelcic J, Aganovic I & Korsic M. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009 36 70-74. (doi:10.1007/s12020-009-9186-y)
34. van der Pas R, de Bruin BC, Leebeek FW, de Maat MP, Rijken DC, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM et al. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. Journal of Clinical Endocrinology and Metabolism 2012 97 1303-1310. (doi:10.1210/jc.2011-2753)
35. Coelho MC, Vieira NL, Kasuki L, Wildemberg LE, Santos CV, Castro G, Gouvea G, Veloso OC, Gadelha T & Gadelha MR. Rotation thromboelastometry and the hypercoagulable state in Cushing's syndrome. Clinical Endocrinology 2014 81 657-664. (doi:10.1111/cen. 12491)
36. Ikkala E, Myllyla G, Pelkonen R, Rasi V, Viinikka L & Ylikorkala O. Haemostatic parameters in Cushing's syndrome. Acta Medica Scandinavica 1985 217 507-511. (doi:10.1111/j.0954-6820.1985.tb03254.x)
37. Patrassi GM, Dal Bo ZR, Boscaro M, Martinelli S & Girolami A. Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thrombosis and Haemostasis 1985 54 518-520.
38. Jenkins PV, Rawley O, Smith OP & O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. British Journal of Haematology 2012 157 653-663. (doi:10.1111/j.1365-2141.2012.09134.x)
39. Dal Bo ZR, Fornasiero L, Boscaro M, Cappellato G, Fabris F & Girolami A. Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. Thrombosis and Haemostasis 1982 47 116-117.
40. de Moerloose P, Boehlen F & Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Seminars in Thrombosis and Hemostasis 2010 36 7-17. (doi:10.1055/s-0030-1248720)
41. Ambrosi B, Sartorio A, Pizzocaro A, Passini E, Bottasso B & Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Experimental and Clinical Endocrinology & Diabetes 2000 108 294-298. (doi:10.1055/s-2000-8000)
42. Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. Journal of Internal Medicine 2005 257 209-223. (doi:10.1111/j.1365-2796.2004.01444.x)
43. Swiatkowska-Stodulska R, Kaniuka-Jakubowska S, Wisniewski P, Skibowska-Bielinska A & Sworczak K. The estimation of selected endogenous anticoagulation system parameters in patients with subclinical Cushing's syndrome. European Journal of Endocrinology 2011 165 865-871. (doi:10.1530/EJE-11-0535)
44. Maclean PS & Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007 67 1429-1440. (doi:10.2165/00003495-200767100-00005)
45. Cesarman-Maus G & Hajjar KA. Molecularmechanisms of fibrinolysis. British Journal of Haematology 2005 129 307-321. (doi:10.1111/j.1365-2141.2005.05444.x)
46. Shibli-Rahhal A, Van Beek M & Schlechte JA. Cushing's syndrome. Clinics in Dermatology 2006 24 260-265. (doi:10.1016/j.clindermatol. 2006.04.012)
47. Miyazato M, Ishidoya S, Satoh F, Morimoto R, Kaiho Y, Yamada S, Ito A, Nakagawa H, Ito S & Arai Y. Surgical outcomes of laparoscopic adrenalectomy for patients with Cushing's and subclinical Cushing's syndrome: a single center experience. International Urology and Nephrology 2011 43 975-981. (doi:10.1007/s11255-011-9950-9)
48. Sahin SB, Cetinkalp S, Erdogan M, Cavdar U, Duygulu G, Saygili F, Yilmaz C & Ozgen AG. Pituitary apoplexy in an adrenocorticotropinproducing pituitary macroadenoma. Endocrine 2010 38 143-146. (doi:10.1007/s12020-010-9367-8)
49. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B & Cooper C. Use of oral corticosteroids in the United Kingdom. QJM: Monthly Journal of the Association of Physicians 2000 93 105-111. (doi:10.1093/qjmed/93.2.105)
50. Rhen T & Cidlowski JA. Antiinflammatory action of glucocorticoids -new mechanisms for old drugs. New England Journal of Medicine 2005 353 1711-1723. (doi:10.1056/NEJMra050541)
51. Fardet L, Petersen I & Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ 2012 345 e4928. (doi:10.1136/bmj.e4928)
52. Xu J, Lupu F & Esmon CT. Inflammation, innate immunity and blood coagulation. Hämostaseologie 2010 30 5-9.
53. Thachil J. Steroids and arteriovenous thrombosis: the role of underlying disease. Chest 2013 143 1836. (doi:10.1378/chest.12-3096)
54. Schulze H & Shivdasani RA. Mechanisms of thrombopoiesis. Journal of Thrombosis and Haemostasis 2005 3 1717-1724. (doi:10.1111/j.1538-7836.2005.01426.x)
55. Jilma B, Cvitko T, Winter-Fabry A, Petroczi K, Quehenberger P & Blann AD. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thrombosis and Haemostasis 2005 94 797-801. (doi:10.1160/TH04-10-0652)
56. Uddhammar A, Rantapaa-Dahlqvist S & Nilsson TK. Long-term follow up of von Willebrand factor and plasminogen activator inhibitor-1 in patients with polymyalgia rheumatica. Annals of the Rheumatic Diseases 1997 56 698-699. (doi:10.1136/ard.56.11.698)
57. Cines DB & Blanchette VS. Immune thrombocytopenic purpura. New England Journal of Medicine 2002 346 995-1008. (doi:10.1056/NEJMra010501)
58. Mizutani H, Furubayashi T, Imai Y, Kashiwagi H, Honda S, Take H, Kurata Y, Yonezawa T, Tarui S & Ikehara S. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW!BXSB) F1. Blood 1992 79 942-947.
59. Rock G, Porta C & Bobbio-Pallavicini E. Thrombotic thrombocytopenic purpura treatment in year 2000. Haematologica 2000 85 410-419.
60. Pisciotto P, Rosen D, Silver H, Genco P, Blumberg N, Katz AJ & Morse EE. Treatment of thrombotic thrombocytopenic purpura. Evaluation of plasma exchange and review of the literature. Vox Sanguinis 1983 45 185-196. (doi:10.1111/j.1423-0410.1983.tb01904.x)
61. Byrnes JJ, Baquerizo H, Gonzalez M & Hensely GT. Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy. American Journal of Hematology 1986 21 299-304. (doi:10.1002/ajh.2830210309)
62. van Giezen JJ & Jansen JW. Inhibition of fibrinolytic activity in-vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation. Thrombosis and Haemostasis 1992 68 69-73.
63. van Giezen JJ, Brakkee JG, Dreteler GH, Bouma BN & Jansen JW. Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis. Blood Coagulation & Fibrinolysis 1994 5 249-255. (doi:10.1097/00001721-199404000-00015)
64. Thong KL, Mant MJ & Grace MG. Lack of effect of prednisone administration on bleeding time and platelet function of normal subjects. British Journal of Haematology 1978 38 373-380. (doi:10.1111/j.1365-2141.1978.tb01057.x)
65. Rosenkrantz B, Naray-Fejes-Toth A, Fejes-Toth G, Fischer C, Sawada M & Frolich JC. Dexamethasone effect on prostanoid formation in healthy man. Clinical Science 1985 68 681-685.
66. Ridker PM, Buring JE & Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001 103 491-495. (doi:10.1161/01. CIR.103.4.491)
67. Baranyai R, Nonell A, Deuschle M & Lederbogen F. How depression may increase cardiac risk: effect of hypercortisolism on platelet activation markers: preliminary data. Neuropsychobiology 2008 57 146-150. (doi:10.1159/000142362)
68. Huang LQ, Whitworth JA & Chesterman CN. Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. Blood Coagulation & Fibrinolysis 1995 6 438-445. (doi:10.1097/00001721-199507000-00011)
69. Kerachian MA, Cournoyer D, Harvey EJ, Chow TY, Neagoe PE, Sirois MG & Seguin C. Effect of high-dose dexamethasone on endothelial haemostatic gene expression and neutrophil adhesion. Journal of Steroid Biochemistry and Molecular Biology 2009 116 127-133. (doi:10.1016/j.jsbmb.2009.05.001)
70. van Zaane B, Nur E, Squizzato A, Gerdes VE, Buller HR, Dekkers OM & Brandjes DP. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. Journal of Thrombosis and Haemostasis 2010 8 2483-2493. (doi:10.1111/j.1538-7836.2010.04034.x)
71. Nordborg E, Andersson R, Tengborn L, Eden S & Bengtsson BA. von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis. Annals of the Rheumatic Diseases 1991 50 316-320. (doi:10.1136/ard.50.5.316)
72. Ciompi ML, Marotta G, Puccetti L, Remorini E, Petrini G, Zuccotti M, Vispi M, Baicchi U & Iacconi P. Behaviour of von Willebrand factor antigen in follow-up of polymyalgia rheumatica/giant cell arteritis. Scandinavian Journal of Rheumatology 1988 17 491-495. (doi:10.3109/03009748809098813)
73. Kagawa H, Okubo S & Yasunaga K. Plasma coagulation and fibrinolysis parameters in patients with collagen diseases, and analysis of the multimeric structure of von Willebrand factor (vWF). International Journal of Hematology 1991 54 429-439.
74. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, Hsieh CM, Chui DS, Thomas KL, Prorock AJ et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nature Medicine 2002 8 473-479. (doi:10.1038/nm0502-473)
75. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. Journal of Thrombosis and Haemostasis 2006 4 1186-1193. (doi:10.1111/j.1538-7836.2006.01949.x)
76. Perry CG, Spiers A, Cleland SJ, Lowe GD, Petrie JR & Connell JM. Glucocorticoids and insulin sensitivity: dissociation of insulin's metabolic and vascular actions. Journal of Clinical Endocrinology and Metabolism 2003 88 6008-6014. (doi:10.1210/jc.2002-021605)
77. Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, Lip GY, Reddy S & Kickler TS. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thrombosis Research 2006 118 247-252. (doi:10.1016/j.thromres.2005.06.006)
78. Lerzo F, Peri G, Doni A, Bocca P, Morandi F, Pistorio A, Carleo AM, Mantovani A, Pistoia V & Prigione I. Dexamethasone prophylaxis in pediatric open heart surgery is associated with increased blood long pentraxin PTX3: potential clinical implications. Clinical & Developmental Immunology 2011 2011 730828. (doi:10.1155/2011/730828)
79. Princen HM, Moshage HJ, de Haard HJ, van Gemert PJ & Yap SH. The influence of glucocorticoid on the fibrinogen messenger RNA content of rat liver in vivo and in hepatocyte suspension culture. Biochemical Journal 1984 220 631-637.
80. Gudmundsson M, Nordborg E, Bengtsson BA & Bjelle A. Plasma viscosity in giant cell arteritis as a predictor of disease activity. Annals of the Rheumatic Diseases 1993 52 104-109. (doi:10.1136/ard.52.2.104)
81. Costallat LT, Ribeiro CC & Annichino-Bizzacchi JM. Antithrombin, protein S and protein C and antiphospholipid antibodies in systemic lupus erythematosus. Sangre 1998 43 345-348.
82. Oner AF, Bay A, Kuru M, Uner A, Arslan S & Caksen H. Effects of high-dose methylprednisolone therapy on coagulation factors in patients with acute immune thrombocytopenic purpura. Clinical and Applied Thrombosis/Hemostasis 2005 11 489-492. (doi:10.1177/107602960501100418)
83. Barettino D, Masia S, Monto F, Perez P, D'Ocon P, Moreno L & Muedra V. Glucocorticoids as modulators of expression and activity of antithrombin (At): potential clinical relevance. Thrombosis Research 2015 135 183-191. (doi:10.1016/j.thromres.2014.10.026)
84. Boffa MB, Hamill JD, Maret D, Brown D, Scott ML, Nesheim ME & Koschinsky ML. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. Journal of Biological Chemistry 2003 278 9250-9257. (doi:10.1074/jbc. M209588200)
85. van Zonneveld AJ, Curriden SA & Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. PNAS 1988 85 5525-5529. (doi:10.1073/pnas.85.15.5525)
86. He G, Pedersen SB, Bruun JM & Richelsen B. Regulation of plasminogen activitor inhibitor-1 in human adipose tissue: interaction between cytokines, cortisol and estrogen. Hormone and Metabolic Research 2000 32 515-520. (doi:10.1055/s-2007-978679)
87. Darmon P, Dadoun F, Boullu-Ciocca S, Grino M, Alessi MC & Dutour A. Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. American Journal of Physiology. Endocrinology and Metabolism 2006 291 E995-E1002. (doi:10.1152/ajpendo.00654.2005)
88. Dover AR, Hadoke PW, Walker BR & Newby DE. Acute effects of glucocorticoids on endothelial fibrinolytic and vasodilator function in humans. Journal of Cardiovascular Pharmacology 2007 50 321-326. (doi:10.1097/FJC.0b013e3180cab148)
89. Shargorodsky J, Hartnick CJ & Lee GS. Dexamethasone and postoperative bleeding after tonsillectomy and adenotonsillectomy in children: a meta-analysis of prospective studies. Laryngoscope 2012 122 1158-1164. (doi:10.1002/lary.21881)
90. Sauerland S, Nagelschmidt M, Mallmann P & Neugebauer EA. Risks and benefits of preoperative high dosemethylprednisolone in surgical patients: a systematic review. Drug Safety 2000 23 449-461. (doi:10.2165/00002018-200023050-00007)
91. Cosgriff SW, Diefenbach AF & Vogt W Jr. Hypercoagulability of the blood associated with ACTH and cortisone therapy. American Journal of Medicine 1950 9 752-756. (doi:10.1016/0002-9343(50)90290-7)
92. Cosgriff SW. Thromboembolic complications associated with ACTH and cortisone therapy. Journal of the American Medical Association 1951 147 924-926. (doi:10.1001/jama.1951.03670270014006)
93. Albucher JF, Vuillemin-Azais C, Manelfe C, Clanet M, Guiraud-Chaumeil B & Chollet F. Cerebral thrombophlebitis in three patients with probable multiple sclerosis. Role of lumbar puncture or intravenous corticosteroid treatment. Cerebrovascular Diseases 1999 9 298-303. (doi:10.1159/000015982)
94. Huerta C, Johansson S, Wallander MA & Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of InternalMedicine 2007 167935-943. (doi:10.1001/archinte.167.9.935)
95. Johannesdottir SA, Horvath-Puho E, Dekkers OM, Cannegieter SC, Jorgensen JO, Ehrenstein V, Vandenbroucke JP, Pedersen L & Sorensen HT. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Internal Medicine 2013 173 743-752. (doi:10.1001/jamainternmed. 2013.122)
96. Stuijver DJ, Majoor CJ, van Zaane B, Souverein PC, de Boer A, Dekkers OM, Buller HR & Gerdes VE. Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest 2013 143 1337-1342. (doi:10.1378/chest.12-1446)
97. Charmandari E, Nicolaides NC & Chrousos GP. Adrenal insufficiency. Lancet 2014 383 2152-2167. (doi:10.1016/S0140-6736(13)61684-0)
98. Squizzato A, Gerdes VE, Ageno W& Buller HR. The coagulation system in endocrine disorders: a narrative review. Internal and Emergency Medicine 2007 2 76-83. (doi:10.1007/s11739-007-0026-X)
99. Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, Falorni A, Gan EH, Hulting AL, Kasperlik-Zaluska A et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. Journal of Internal Medicine 2014 275 104-115. (doi:10.1111/joim.12162)
100. Ketha S, Smithedajkul P, Vella A, Pruthi R, Wysokinski W & McBane R. Adrenal haemorrhage due to heparin-induced thrombocytopenia. Thrombosis and Haemostasis 2013 109 669-675. (doi:10.1160/TH12-11-0865)
101. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006 4 295-306. (doi:10.1111/j.1538-7836.2006. 01753.x)
102. Uthman I, Salti I & Khamashta M. Endocrinologic manifestations of the antiphospholipid syndrome. Lupus 2006 15 485-489. (doi:10.1191/0961203306lu2318rr)
103. Ramon I, Mathian A, Bachelot A, Hervier B, Haroche J, Boutin-Le Thi Huong D, Costedoat-Chalumeau N, Wechsler B, Karmali R, Velkeniers B et al. Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. Journal of Clinical Endocrinology and Metabolism 2013 98 3179-3189. (doi:10.1210/jc. 2012-4300)
104. Behera KK, Kapoor N, Seshadri MS & Rajaratnam S. Acute adrenal insufficiency due to primary antiphospholipid antibody syndrome. Indian Journal of Endocrinology and Metabolism 2013 17 (Suppl 1) S240-S242. (doi:10.4103/2230-8210.119584)
105. Satta MA, Corsello SM, Della CS, Rota CA, Pirozzi B, Colasanti S, Cina G, Grossman AB & Barbarino A. Adrenal insufficiency as the first clinical manifestation of the primary antiphospholipid antibody syndrome. Clinical Endocrinology 2000 52 123-126. (doi:10.1046/j. 1365-2265.2000.00903.x)
106. Winternitz WW. Adrenal hemorrhage complicating anticoagulant therapy. Southern Medical Journal 1983 76 1369-1371. (doi:10.1097/00007611-198311000-00010)
107. Junqueira DR. American College of Chest Physicians guidelines for heparin-induced thrombocytopenia: a need for evidence-based assessment of the baseline risk of heparin-induced thrombocytopenia. Chest 2013 143 1190-1191. (doi:10.1378/chest.12-2926)
108. Rosenberger LH, Smith PW & Sawyer RG. Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage. Journal of the American Geriatrics Society 2011 59 1157-1158. (doi:10.1111/j.1532-5415.2011.03427.x)
109. Soran H, Osman HY, Younis N, Sukumar SA & Taberner DA. Could factor V Leiden defect cause Addison's disease? QJM: Monthly Journal of the Association of Physicians 2001 94 721-722. (doi:10.1093/qjmed/94.12.721)
110. Derex L, Giraud P, Hanss M, Riche H, Nighoghossian N & Trouillas P. Spontaneous intracerebral hemorrhage revealing Addison's disease. Cerebrovascular Diseases 1998 8 240-243. (doi:10.1159/000015858)
111. Shivaprasad C. Sheehan's syndrome: newer advances. Indian Journal of Endocrinology and Metabolism 2011 15 (Suppl 3) S203-S207. (doi:10.4103/2230-8210.84869)
112. Kronvall E, Valdemarsson S, Saveland H & Nilsson OG. High prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a long-term prospective study using dynamic endocrine testing. World Neurosurgery 2015 83 574-582. (doi:10.1016/j.wneu. 2014.12.007)
113. Hannon MJ, Behan LA, O'Brien MM, Tormey W, Javadpour M, Sherlock M & Thompson CJ. Chronic hypopituitarism is uncommon in survivors of aneurysmal subarachnoid haemorrhage. Clinical Endocrinology 2015 82 115-121. (doi:10.1111/cen.12533)
114. Setian N, Tanaka CM, Damiani D, Dichtchekenian V, Carneiro JD & D'Amico EA. Hypopituitarism, deficiency of factors V and VIII and von Willebrand factor: an uncommon association. Journal of Pediatric Endocrinology & Metabolism 2002 15 331-333. (doi:10.1515/JPEM. 2002.15.3.331)
115. Peacey SR, Wright D, Aye M & Moisey R. Glucocorticoid replacement therapy and fibrinolysis in patients with hypopituitarism. Clinical Endocrinology 2012 77 94-98. (doi:10.1111/j.1365-2265.2011.04314.x)